Here's Why We're Not At All Concerned With InSilico Medicine Cayman TopCo's (HKG:3696) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?
Given this risk, we thought we'd take a look at whether InSilico Medicine Cayman TopCo (HKG:3696) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). First, we'll determine its cash runway by comparing its cash burn with its cash reserves.
When Might InSilico Medicine Cayman TopCo Run Out Of Money?
A company's cash runway is calculated by dividing its cash hoard by its cash burn. In December 2025, InSilico Medicine Cayman TopCo had US$447m in cash, and was debt-free. Looking at the last year, the company burnt through US$80m. Therefore, from December 2025 it had 5.6 years of cash runway. Importantly, though, analysts think that InSilico Medicine Cayman TopCo will reach cashflow breakeven before then. In that case, it may never reach the end of its cash runway. Depicted below, you can see how its cash holdings have changed over time.
See our latest analysis for InSilico Medicine Cayman TopCo
How Well Is InSilico Medicine Cayman TopCo Growing?
Some investors might find it troubling that InSilico Medicine Cayman TopCo is actually increasing its cash burn, which is up 37% in the last year. And we must say we find it concerning that operating revenue dropped 34% over the same period. Taken together, we think these growth metrics are a little worrying. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.
How Easily Can InSilico Medicine Cayman TopCo Raise Cash?
InSilico Medicine Cayman TopCo seems to be in a fairly good position, in terms of cash burn, but we still think it's worthwhile considering how easily it could raise more money if it wanted to. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.
Since it has a market capitalisation of US$2.9b, InSilico Medicine Cayman TopCo's US$80m in cash burn equates to about 2.7% of its market value. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the cash by issuing a few shares.
Is InSilico Medicine Cayman TopCo's Cash Burn A Worry?
It may already be apparent to you that we're relatively comfortable with the way InSilico Medicine Cayman TopCo is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. While its falling revenue wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Its important for readers to be cognizant of the risks that can affect the company's operations, and we've picked out 1 warning sign for InSilico Medicine Cayman TopCo that investors should know when investing in the stock.
If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.